Sectors of the Indian Economy - Class 10 Study Notes pdf
Renal transplantation.pptx
1. Anesthesia for Living Donor Renal
Transplantation
DR:IBRAHIM HASSAAN,MBCHB,MSC,EDAIC
07/07/2023
2.
3.
4. A-Preoperative Assessment specific to Chronic Kidney
Disease
History
• Assess underlying condition—DM,HTN etc (controlled,
medication,complications)
• Symptoms of ESRD: asymptomatic, fatigue, weakness, confusion, nausea,
vomiting, paresthesias, dyspnea, pruritus, nocturia, reduced urine output
• Comorbid disease
• Previous abdominal surgery (scarring/adhesions can make dissection difficult
and increase blood loss)
5. 1-Current renal replacement therapy
How intraperitoneal/ hemodialysis /When done?
2-Volume status, current weight, dry weight?
3- Electrolytes?
4-Vascular access sites, current and past, fistula ?
5-Planned post operative dialysis
6. Medication history:
- high-dose ACE inhibitors should be withheld perioperatively unless there is left
ventricular dysfunction.
- beta-blockers, statins and aspirin should not be stopped perioperatively.
- continue diuretics in the perioperative period.
7. Physical Exam
ESRD: altered mental status, neuropathies, hyperreflexia, seizures, weight loss, HTN,
dependent edema, orthostatic hypotension
• Sites for IV access, central access
-Gastrointestinal
-peripheral neuropathy, autonomic neuropathy
-Haematological – anaemia, thrombocytopenia, coagulopaty
-Endocrine/ metabolic – Hyperparathyroidism, Mg,Na,Cl
acidosis, impaired thermoregulation, hypervolaemia (compare to patient’s dry weight)
-Immunological – decreased immune function, intercurrent infection, Hepatitis C
infection from dialysis,
-Vascular access – fistula sites and functionality, current and previous central venous
access
9. B-Anesthetic care
Preop-
- AV fistula wrapped and padded. Patency checked at regular
intervals.
-monitors
Arterial line, blood pressure cuff placed on the opposite side
Monitoring central venous access, ECG with ST segment
monitoring, neuromuscular and temperature.
10. Induction
GA/ETT with RSI as required
- Aim normothermic, normotensive, normal intravascular volume.
- Target CVP >10-12 mmHg, If PAC insitu target pulmonary artery diatolic
pressure >15mmHg
- Typical volume required 60-100 ml/kg
- Type of fluids less important
- Prompt replacement of blood if sudden massive haemorrhage to preserve
kidney perfusion
11. How can the function of the transplanted
kidney be optimized intraoperatively?
General measures
- General anaesthesia with paralysis and ventilation allows better haemodynamic
control and muscle relaxation than that of regional anaesthesia.
This also avoids the risk of coughing and anastomotic breakdown.
- Maintain normothermia, normoxia, normocapnia, normoglycaemia
12. Specific to renal transplant
- MAP of 90mmHg ;aim is to maintain adequate hydration and renal perfusion (adjusted
higher for Maintain normotension at the time of graft arterial clamp removal to
optimise graft perfusion.
- Maintain a CVP of 12-14cm H2O at the time of graft perfusion.
- Cardiac output monitoring to guide fluid management.
-Liberal fluid administration at the beginning of surgery but keeping
total infusion volumes less than 2.5L.
- Blood transfusion with a transfusion target of 70g/L will improve
oxygen delivery to the transplanted kidney.
13. Drugs to improve graft function
- Dopamine as an infusion to improve renal blood flow
- Furosemide (40-250mg IV) as a bolus prior to reperfusion to promote diuresis,
renal blood flow and avoid oliguria.
- Mannitol (0.5g/kg IV) as a bolus prior to reperfusion to increase intravascular
volume and improve renal blood flow
14. C-Postoperative
PACU or ICU as required
• Monitor for bleeding, metabolic dysfunction
•Treat hypotension hypovolemia, monitor arterial and central venous pressure
Isotonic 0.9% saline at 30ml/hr plus previous hour urine output
Pain Management
PCA morphine used with care, epidural can be used, avoid hypotension.
TAP block with multimodal analgesia can be adequate.
15. Common Postoperative Analgesic drugs
should be Avoided
Non-steroidal anti-inflammatory drugs are contraindicated
as they inhibit prostaglandin synthesis and therefore reduce renal blood
flow and glomerular filtration autoregulation.
Cyclo-oxygenase 2 inhibitors should also be avoided due a similar
mechanism.